Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 9 August 2017

Shire plc : Director/PDMR Shareholding

Shire plc    

Published: 15:15 CEST 09-08-2017 /GlobeNewswire /Source: Shire plc / : SHP /ISIN: JE00B2QKY057

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding
 
August 9, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
 
Notification of transaction by person discharging managerial responsibilities and person closely associated with them
 

1.

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")

a)

Name

Kim Stratton / Peter Stratton

2.

Reason for the notification

a)

Position / status

Head of International Commercial (PDMR) / PCA of Kim Stratton

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor

a)

Name

Shire plc

b)

LEI

54930005LQRLI2UXRQ59

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")

 

 

Identification code

ISIN: JE00B2QKY057

b)

Nature of the transaction

Transfer of Ordinary Shares held by Kim Stratton to a joint account held by Kim Stratton and Peter Stratton and the pledge of such Ordinary Shares as security for a loan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

5,943

d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)

e)

Date of the transaction

August 8, 2017

f)

Place of the transaction

Outside a trading venue

 

Oliver Strawbridge

Senior Assistant Company Secretary

 

For further information please contact:

 

Investor Relations

 

 

Ian Karp

ikarp@shire.com

+1 781 482 9018

Robert Coates

rcoates@shire.com

+44 1256 894874

Media

 

 

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Debbi Ford

debbi.ford@shire.com 

+1 617 949 9083

 

 

NOTES TO EDITORS

 

About Shire

 

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Shire plc, 1 Kingdom Street Paddington, London W2 6BD, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.